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Summary
 
The 
 
N
 
-formylpeptide receptor (FPR) is a G protein–coupled receptor that mediates mamma-
lian phagocyte chemotactic responses to bacterial 
 
N
 
-formylpeptides. Here we show that a
mouse gene named 
 
Fpr-rs2
 
 encodes a second 
 
N
 
-formylpeptide receptor subtype selective for
neutrophils which we have provisionally named FPR2. The prototype 
 
N
 
-formylpeptide fMLF
induced calcium flux and chemotaxis in human embryonic kidney (HEK) 293 cells stably
transfected with FPR2. The EC
 
50
 
s, 
 
z
 
5 
 
m
 
M for calcium flux and chemotaxis, were 
 
z
 
100-fold
greater than
 
 
 
the corresponding values for mouse FPR-transfected HEK 293 cells. Consistent
with this, fMLF induced two distinct concentration optima for chemotaxis of normal mouse
neutrophils, but only the high concentration optimum for chemotaxis of neutrophils from
FPR knockout mice. Based on these data, we hypothesize that high- and low-affinity 
 
N
 
-for-
mylpeptide receptors, FPR and FPR2, respectively, may function in vivo as a relay mediating
neutrophil migration through the high and low concentration portions of 
 
N
 
-formylpeptide
gradients.
Key words: chemoattractant • inﬂammation • neutrophil • G protein–coupled receptor • 
phagocyte
 
T
 
he 
 
N
 
-formylpeptides are cleavage products of bacterial
and mitochondrial proteins, and serve as powerful
chemoattractants for mammalian phagocytes (1–3). Based
on their chemotactic actions, it has been hypothesized that
 
N
 
-formylpeptides attract phagocytes to sites of infection
and therefore play an important role in antibacterial host
defense (4). Like other chemoattractants, they act through
seven-transmembrane-domain G protein–coupled recep-
tors (5).
Two functional 
 
N
 
-formylpeptide receptors, designated
FPR and FPRL1R, and one related putative receptor, des-
ignated FPRL2, have been identified by human gene clon-
ing (6–11). FPR and FPRL1R bind the prototypical 
 
N
 
-for-
mylpeptide fMet-Leu-Phe (fMLF) with high and low affinity,
respectively. The 
 
K
 
d
 
 for FPR is 
 
z
 
3 nM, whereas that for
FPRL1R is 
 
.
 
100 times higher (10, 12). fMLF has been re-
ported to induce calcium mobilization in cells transfected
with FPR or FPRL1R and chemotaxis in cells transfected
with FPR, but does not induce chemotaxis in cells trans-
fected with FPRL1R when tested at concentrations as high
as 2 
 
m
 
M (8, 10, 13, 14). FPRL1R has also been reported to
bind lipoxin A
 
4
 
, a lipid derivative of arachidonate metabo-
lism, with high affinity. Functions of lipoxin A
 
4
 
 mediated
by FPRL1R include induction of GTPase activity and pro-
duction of arachidonic acid; however, it has not been
shown to induce calcium flux or chemotaxis (15). To our
knowledge, FPRL1R is the only receptor whose agonists
include both a peptide and a lipid. Recently, the range of
potential biological actions of FPRL1R has become further
complicated by the discovery that serum amyloid A (SAA),
an acute phase reactant in inflammation, and T21, an
ectodomain peptide of HIV-1 gp41, are also functional
ligands for FPRL1R (16, 17). A second gp41 peptide
named T20, which is a powerful blocker of HIV-1 entry
currently in clinical trials, has been reported to be a func-
tional ligand for FPR (18, 19).
To identify biological roles for these molecules, we have
been studying their mouse counterparts. We previously
characterized mouse FPR and have developed mice lacking
this receptor by targeted gene deletion (20, 21). FPR
 
2
 
/
 
2
 
mice revealed an important role for FPR in innate host de-
fense against 
 
Listeria monocytogenes
 
 (21). We have also 
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cloned five related mouse genes, designated 
 
Fpr-rs1
 
, 
 
Fpr-
rs2
 
, 
 
Fpr-rs3
 
, 
 
Fpr-rs4
 
, and 
 
Fpr-rs5
 
 (22). Extensive cross-
hybridization analysis failed to find more than three related
human genes, indicating that the FPR gene cluster has un-
dergone differential lineage-specific expansion in mammals.
This has created problems in defining orthologous relation-
ships, particularly in defining the mouse FPRL1 ortho-
logue. 
 
Fpr-rs1
 
 and 
 
Fpr-rs2
 
 are most similar to human
FPRL1 (both show 
 
z
 
75% nucleotide identity in the open
reading frame [ORF]), whereas the other three genes form
a separate cluster with slightly lower sequence relatedness
to FPRL1 (22). Like FPRL1, both 
 
Fpr-rs1
 
 and 
 
Fpr-rs2
 
 are
expressed in leukocytes, although expression in specific
leukocyte subsets has not previously been defined.
Chinese hamster ovary (CHO) cells transfected with 
 
Fpr-
rs1
 
 have been demonstrated to bind lipoxin A
 
4
 
, and the en-
coded receptor has therefore been named LXA
 
4
 
R (23).
This suggested that 
 
Fpr-rs1
 
 is the orthologue of FPRL1 but
raised unanswered questions about its specificity for 
 
N
 
-for-
mylpeptides and about the ligand specificity of 
 
Fpr-rs2
 
, as
well as about the functional relationship of these molecules
to FPR. Here we show that 
 
Fpr-rs2
 
 encodes a second
mouse neutrophil fMLF receptor subtype, which we now
provisionally name FPR2, which operates at higher con-
centrations of ligand than FPR.
 
Materials and Methods
 
Mouse Leukocyte Purification.
 
Development of FPR knockout
mice has been described previously (21). Mice used in this study
were from FPR
 
1
 
/
 
2
 
 
 
3
 
 FPR
 
1
 
/
 
2
 
 matings of an F1 backcross of
FPR
 
1
 
/
 
2
 
 129/Sv with wild-type C57Bl/6 mice. Leukocytes were
harvested from the peritoneal cavity of FPR
 
1
 
/
 
1
 
 and FPR
 
2
 
/
 
2
 
mice after thioglycollate (TG) irritation, as described previously
(21). Cells obtained after 3 h were 
 
.
 
90% neutrophils, whereas
cells obtained after 72 h were 
 
.
 
90% macrophages, as determined
by the morphologic appearance of Diff-Quick-stained prepara-
tions.
 
RNA Analysis.
 
Cells were lysed, and total RNA was pre-
pared using the RNA STAT-60 protocol (Tel-Test, Inc.). RNA
(10 
 
m
 
g) was separated on a denaturing agarose gel, and Northern
blots were prepared by standard methods (24). Blots were hybrid-
ized with a full-length 
 
Fpr-rs2
 
 ORF probe, which was labeled
with 
 
32
 
P-dCTP using a random-primer DNA labeling kit (Boeh-
ringer Mannheim). To control for RNA loading, the blots were
also probed separately with a 49-bp oligonucleotide from the 5
 
9
 
terminal end of the actin gene, which was labeled with a DNA 5
 
9
 
end labeling kit (Boehringer Mannheim).
 
Creation of a Cell Line Expressing FPR2.
 
The 
 
Fpr-rs2
 
 ORF was
amplified from genomic clone 7 (22) using the upper strand
primer 5
 
9
 
-ATATAAGCTTGCCACC
 
ATG
 
GATTATAAAGA-
TGATGATGATAAA
 
GAATTC
 
GAATCCAACTACTCCAT-
CCATCTGAATG-3
 
9
 
, which contains a Flag epitope tag (under-
lined), an EcoRI site (italicized), and an ATG initiating codon
(bold); and lower strand primer 5
 
9
 
-CG
 
CTCGAG
 
TCA
 
TGGG-
GCCTTTAACTCAATGTCTG-3
 
9
 
, which contains an XhoI site
(italicized sequence) and the termination codon (bold). The
1.1-kb PCR fragment was then ligated into pCR2.1. Sequence
fidelity was verified, and the correct insert was then subcloned
between the NotI and XhoI sites of pcDNA3 (Invitrogen). Hu-
man embryonic kidney (HEK) 293 cells were maintained in
DMEM  with 10% FBS. 10
 
7
 
 cells in log phase were electroporated
with 20 
 
m
 
g of plasmid DNA using a GenePulser (Bio-Rad Labo-
ratories). Cell colonies resistant to 2 g/liter G-418 (GIBCO
BRL) were isolated and expanded in DMEM with 10% FBS and
2 g/liter G-418.
 
Intracellular [Ca
 
2
 
1
 
] Measurements.
 
Cells (
 
z
 
10
 
7
 
/ml) were incu-
bated in HBSS and 2.5 
 
m
 
M Fura-2 AM (Molecular Probes, Inc.)
for 30–60 min at 37
 
8
 
C in the dark. The cells were then washed
with HBSS and resuspended at 10
 
7
 
 cells/ml. 4 
 
3 
 
10
 
6
 
 cells were
stimulated in a total volume of 2 ml in a continuously stirred cu-
vette at 37
 
8
 
C in a fluorimeter (Photon Technology, Inc.). fMLF,
MLF, and recombinant C5a were obtained from Sigma Chemical
Co. The chemokines IL-8, macrophage-inflammatory protein
(MIP)-1
 
b
 
, and monocyte-chemotactic protein (MCP)-3 were
obtained from Peprotech. The data were recorded every 200 ms
as the relative ratio of fluorescence emitted at 510 nm after se-
quential excitation at 340 and 380 nm. For some experiments,
cells were incubated with 250 ng/ml pertussis toxin for 4 h be-
fore functional assay.
 
Chemotaxis.
 
HEK 293 cells were detached from flasks by re-
placing media with 0.05% trypsin (Quality Biological) and incu-
bating at room temperature for 
 
z
 
1 min. DMEM containing 20%
FBS was added, and the cells were harvested, pelleted, and resus-
pended at 10
 
6
 
 cells/ml in RPMI 1640 supplemented with 1%
BSA and 20 mM Hepes. fMLF was loaded at varying concentra-
tions in the lower compartment of a 48-well microchemotaxis
chamber (NeuroProbe). To distinguish chemotaxis from chemo-
kinesis, additional experiments were carried out in which an
equal concentration of fMLF was tested simultaneously in the up-
per and lower compartments. The chamber was soaked in 1%
SDS overnight and washed before each experiment. A polyvi-
nylpyrrolidone-free polycarbonate filter (10- and 3-
 
m
 
m pores for
HEK 293 cells and neutrophils, respectively) was used. For ex-
periments with HEK 293 cells, the filters were coated with 0.05
mg/ml rat tail collagen in RPMI 1640 and 70 mM Hepes for 2 h
and dried before each experiment. The filter, coated side down,
was placed between the upper and lower compartments of the
chamber, and 50 
 
m
 
l of 10
 
6
 
 HEK 293 cells/ml was loaded in the
upper compartment. The chemotaxis chamber was incubated at
37
 
8
 
C, 100% humidity, and 5% CO
 
2
 
 for 5 h for HEK 293 cells
and 45 min for neutrophils. The filter was then removed,
washed, fixed, and stained. Cells that migrated through the filter
were counted microscopically under high power. All conditions
were tested in triplicate.
 
Results
 
Fpr-rs2 Is Expressed in Mouse Phagocytes.
 
Previously, we
reported that 
 
Fpr-rs2
 
 is expressed in unfractionated periph-
eral blood leukocytes (22). To determine the expression
pattern in finer detail, we used Northern blot hybridization
to probe total RNA from peritoneal cells elicited 3 and 72 h
after instillation of TG. The elicited peritoneal cell populations
were markedly enriched in neutrophils and macrophages at 3
and 72 h, respectively (
 
.
 
90% pure). The residual 10% of
cells were mainly mononuclear cells and neutrophils in the
3- and 72-h cell populations, respectively. Specific mRNA
bands were detected in both the 3- and 72-h TG-elicited
peritoneal cells. In both cases, two classes of transcripts 
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(
 
z
 
1.5 and 1.9 kb) were observed, and the signal strength
was similar for each class within each sample. However,
signals from the 3-h cells were much stronger than from
the 72-h cells (Fig. 1). Note that 72-h RNA was deliber-
ately overloaded relative to 3-h RNA, as revealed by hy-
bridization with an actin probe. A reasonable interpretation
of these results, consistent with the functional data that fol-
lows, is that 
 
Fpr-rs2
 
 is primarily expressed in neutrophils,
and the weak signal in the 72-h cells is due to neutrophils,
which make up a small minority of the total cell popula-
tion. An alternative explanation is that monocytes express
 
Fpr-rs2
 
 in the circulation, but not after extravasation.
 
Fpr-rs2 Encodes a Low-affinity G Protein–coupled FPR.
 
To assess whether 
 
Fpr-rs2
 
 encodes a functional FPR, we
performed a gain-of-function genetic test by measuring
fMLF-induced intracellular Ca
 
2
 
1
 
 flux in HEK 293 cell lines
stably transfected with expression plasmids containing the
 
Fpr-rs1
 
 or 
 
Fpr-rs2
 
 ORFs.
In the initial screen, we tested 16 G-418–resistant HEK
293 cell colonies derived from the same transfection, all of
which responded to 10 
 
m
 
M fMLF. In contrast, nonformyl-
ated MLF at 1 
 
m
 
M, C5a at 10 nM, and the chemokines IL-8,
MIP-1
 
b
 
, and MCP-3 at 100 nM or greater did not induce
a response. Also, 
 
Fpr-rs1
 
–transfected cells, maintained in
the same selective conditions, consistently failed to respond
to fMLF at concentrations as high as 100 mM (Fig. 2 A).
Higher concentrations could not be tested for technical
reasons due to the hydrophobicity of fMLF. Based on this
result, we infer that Fpr-rs2 encodes an FPR, which we
provisionally name FPR2.
Four cell lines that gave particularly strong responses,
designated L4-7, L4-14, L4-15, and L4-16, were selected
for further study. In each case, the calcium flux responses
were concentration dependent and saturable, with an EC50
of 5.3 6 0.3 mM (n 5 5, each cell line tested at least once;
Fig. 2 C). HEK 293 cells transfected with mouse FPR also
exhibited a calcium flux response to fMLF that was con-
centration dependent and saturable; however, the EC50,
z50 nM, was much lower than for FPR2 (Fig. 2 C). This
value is consistent with that previously reported for expres-
sion of mouse FPR in frog oocytes in a calcium-release as-
say (20).
When FPR2-transfected cells were sequentially stimu-
Figure 1. Distribution of FPR2
mRNA in mouse leukocytes. A
Northern blot containing total
RNA from peritoneal cells elic-
ited 3 and 72 h after instillation of
TG (3h TGPC and 72h TGPC)
was serially hybridized to a 32P-
labeled Fpr-rs2 ORF probe en-
coding FPR2 and a 32P-labeled
actin probe, both under high
stringency conditions. 3- and 72-h
TG-elicited peritoneal cells were
enriched in neutrophils and mac-
rophages, respectively (.90%). Af-
ter hybridization with Fpr-rs2 and
actin, the blot was exposed for 3
and 2 d, respectively, to x-ray
film. The positions of 18S and 28S ribosomal bands are indicated at the
right. The 72h TGPC lane was deliberately overloaded with RNA, as in-
dicated by the actin hybridization, to test for low abundance mRNA.
Figure 2. Mouse FPR2 is a G protein–coupled receptor specific for fMLF. Receptor activation was monitored in real time by calcium flux assay. (A)
fMLF specificity. Fpr-rs1– and FPR2-transfected HEK 293 cells were stimulated with 100 mM fMLF at the times indicated by arrows. Responses are in
relative fluorescence units. Results shown for FPR2 are for clone L4-16 and are representative of .5 experiments with this clone and 1 experiment with
15 other FPR2-specific clones. 10 mM ATP, which activates an endogenous ATP signaling pathway, was used as a positive control. (B) Pertussis toxin
blockade of FPR2 signaling. FPR2-transfected cells cultured in the presence and absence of 250 ng/ml pertussis toxin were stimulated with 100 mM
fMLF. As a positive control, toxin-treated cells were also stimulated with 10 mM ATP, which induces pertussis toxin–resistant calcium flux. The results
are representative of four independent experiments. (C) Concentration dependence. Data for each curve are from separate experiments representative of
at least five experiments each for the FPR2 cell line L4-16 and the FPR cell line mFPR-23. Data are derived from the peak amplitude of the calcium
transient at each concentration tested, and are plotted as a fraction of the EC100.744 A Second Mouse N-formylpeptide Receptor Subtype
lated with 100 mM fMLF, no response was observed after
the second stimulation, suggesting complete receptor desen-
sitization by the first stimulus (Fig. 2 A). The fMLF response
could also be abolished by pretreatment of FPR2-express-
ing cells with pertussis toxin, suggesting that the receptor is
coupled to a Gi-type G protein (Fig. 2 B). As a control of
cell integrity, we stimulated toxin-treated cells with 10 mM
ATP, which induced a calcium flux at levels equivalent to
the untreated cells.
To test the mechanism of fMLF induction of calcium
flux in FPR2-transfected cells, we carried out radioligand
binding assays using a 3H-fMLF probe. Although human
and mouse FPR-expressing cells exhibited specific binding,
cells expressing FPR2 did not (data not shown). This is not
surprising, since the highest concentration of 3H-fMLF that
could be meaningfully tested was 640 nM, which is below
the threshold of detection of calcium flux induced by fMLF
in FPR2-transfected cells. In contrast, the threshold for in-
duction of calcium flux by fMLF in human and mouse
FPR-transfected cells is z0.5 and 10 nM, respectively. We
conclude that FPR2 is most likely a low-affinity FPR.
FPR2 Is a Chemotactic Receptor. Given the reactivity of
FPR2 to fMLF observed in the calcium flux assay, we next
tested its ability to mediate chemotaxis. FPR2-expressing
cells migrated in a concentration-dependent manner in re-
sponse to fMLF with a threshold of z1 mM. The EC50 was
z5 mM. In all experiments, the upward phase of the con-
centration–response curve was consistently superimposable
with that of the calcium flux assay for the same FPR2-express-
ing cell line. Mouse FPR-expressing HEK 293 cell mi-
gration followed a clear-cut bell-shaped concentration–
response curve whose EC50 was shifted z10–100-fold to
the left relative to the FPR2 curve (Fig. 3). The activity
was specific for both receptors, since HEK 293 cells trans-
fected with the related gene Fpr-rs1 and selected with
G-418 did not exhibit concentration-dependent migration
in response to fMLF when tested with concentrations rang-
ing from 0.1 nM to 100 mM (Fig. 3 B). To distinguish
chemotaxis from chemokinesis, equal concentrations of fMLF
were added to the upper and lower chambers of the chemo-
taxis apparatus. In this configuration, no dose-dependent cell
migration was observed (Fig. 3 A). Therefore, FPR2 can
not only cause intracellular signaling, but can also use those
signals to elicit a chemotactic action by the cell.
FPR2 May Mediate Mouse Neutrophil Calcium Flux and
Chemotaxis. To determine whether FPR2 may operate as
a second mouse neutrophil fMLF receptor in primary cells,
we examined fMLF responses by cells from FPR knockout
mice. Previously, we reported that neutrophils from these
mice failed to respond to fMLF either in calcium flux or
chemotaxis assays at concentrations as high as 1 mM, and
noted that this correlated well with the concentration–
response relationship for HEK 293 cells expressing mouse
FPR in the calcium flux assay (21).
However, having now discovered that the threshold for
calcium flux in FPR2-expressing cells was z1 mM, we re-
tested neutrophils from these animals at higher concentra-
tions and observed a concentration–response relationship
that was virtually identical for FPR2/2 neutrophils versus
HEK 293 cells expressing FPR2 for both calcium flux and
chemotaxis (Figs. 2–4). The EC50 value in FPR2/2 neutro-
phils was z6 mM for calcium flux, in close agreement with
the value of 5.3 mM cited above for FPR2-expressing
HEK 293 cells (compare Figs. 2 C and 4 A). The chemo-
taxis concentration–response curves were also very similar
(compare Figs. 3 B and 4 B).
Calcium flux and chemotaxis experiments were also per-
formed on neutrophils from wild-type mice using an ex-
panded concentration range relative to what was used in
our previous report, 1 nM to 100 mM (Fig. 4). In the cal-
cium flux assay, the response saturated at 1 mM fMLF,
which corresponds to the saturation concentration for
Figure 3. FPR2 is a chemo-
tactic receptor. HEK 293 cells
stably transfected with mouse
FPR, FPR2, or Fpr-rs1 were in-
cubated in a microchemotaxis
chamber for 5 h, and the number
of migrating cells was counted.
Data shown are from a single ex-
periment representative of more
than five separate experiments in
each panel with a consistent pat-
tern. (A) FPR2 transfectants with
equal concentration of fMLF in
the upper and lower chambers
(fMLF/fMLF, open circles), or
with fMLF in only the lower
chamber (Medium/fMLF, filled
circles). *Statistically significant
difference between the points
shown and baseline migration in
the absence of fMLF, P ,
0.0005 by Student’s t test. (B)
FPR transfectants (circles) and
Fpr-rs1 transfectants (squares).745 Hartt et al. Brief Definitive Report
mouse FPR and the threshold concentration for FPR2
(Fig. 2 C). For chemotaxis, we observed an unusual, mul-
tiphasic concentration–response relationship, which was
equivalent to the sum of the individual relationships for
mouse FPR and FPR2 tested separately in HEK 293 cells
(Fig. 3). A first peak was clearly resolved and consistently
observed between 0.5 and 50 mM, and had an optimum of
5 mM. The curve then passed through a minimum at 50 mM,
and then consistently increased at 100 mM. The second
peak could not be fully resolved due to artifacts induced by
DMSO required to solubilize fMLF at higher concentra-
tions. However, its existence is strongly corroborated by a
dose-dependent increase in migration of neutrophils from
the FPR2/2 mice over the same concentration range.
Discussion
In this study, we have identified dual concentration–
response optima for normal mouse neutrophils in chemotaxis
induced by the proinflammatory chemoattractant fMLF.
For leukocytes, chemoattractant concentration–response
relationships are classically described by a bell-shaped curve
with a single optimum; the presence of a second optimum
as we have described is highly unusual. The functional
characteristics of FPR versus FPR2, the second mouse
neutrophil low-affinity fMLF receptor subtype that we
have identified, in conjunction with analysis of neutrophils
from mice lacking the high-affinity fMLF receptor FPR,
strongly suggest a molecular explanation for this anomaly in
which FPR and FPR2 account for the low and high con-
centration–response optima, respectively.
The significance of this result relates to the dilemma of how
leukocytes navigate through the highest portions of chemoat-
tractant concentration gradients in which their high-affinity
chemoattractant receptors are likely to become deactivated
through receptor phosphorylation and/or sequestration mech-
anisms (25, 26). Our data suggest the hypothesis that distinct
high- and low-affinity receptors for the same chemoattractant
may work as a relay to sensitize the cell throughout the gradi-
ent, allowing it to arrive at the focus of inflammation.
Most work on leukocyte chemotactic receptors has fo-
cused on the identification of receptors that bind ligand in
the low nanomolar range, so-called “high-affinity receptors,”
because binding is easy to measure with available radioli-
gand probes. However, potentially important low-affinity
ligand–receptor interactions have also been identified, such
as multiple CXC chemokines for CXCR1 (27) and MIP-1b
and MCP-1 for CCR1 (28). In this regard, the CXC
chemokine neutrophil-activating peptide 2 (NAP-2) is par-
ticularly interesting since, like fMLF in our study, it appears
to activate neutrophil chemotaxis via two concentration–
response optima by high-affinity binding to CXCR2 and
low-affinity binding to CXCR1 (29).
Alternative mechanisms of navigation may also exist, such
as usage of high-affinity receptors at different points during
the migration path through differential spatial expression of
cognate chemoattractants, or by receptor recycling, or by a
combination of these mechanisms. In this regard, chemo-
kines may be particularly important for fine-tuning leuko-
cyte migration to inflammatory sites.
In humans, the two functional FPRs, FPR and FPRL1R,
also have high and low affinity, respectively, for fMLF (7, 10,
12). Consistent with this, in calcium flux assays, fMLF is
z100-fold more potent at FPR versus FPRL1R in vitro.
This hierarchy is analogous to that for mouse FPR and
FPR2. However, one significant difference is that, to date,
FPRL1R has not been reported to be a chemotactic recep-
tor, and its biological function remains unknown. Therefore,
the discovery of FPR2 represents the first time that two
chemotactic FPRs have been observed in a single species.
FPRL1R also binds lipoxin A4 with high affinity (15), to our
knowledge the only example of a receptor with both peptide
and lipid ligands. In mice, the related gene Fpr-rs1 encodes a re-
ceptor, LXA4R, that binds lipoxin A4 (23). Therefore, it would
Figure 4. Mouse neutrophils
lacking FPR respond to fMLF
with a concentration dependence
matching that of FPR2. Perito-
neal leukocytes elicited by a 3-h
challenge with TG (.90% neu-
trophils) from wild-type mice
(1/1, filled symbols) and FPR
knockout littermates (2/2, open
symbols) were stimulated with
the indicated concentration of
fMLF. (A) Calcium flux. Data
are derived from the peak ampli-
tude of the calcium transient at
each concentration tested, and are
plotted as a fraction of the EC100.
Data are representative of more
than five experiments. (B) Chemo-
taxis.  Conditions were tested in
triplicate. Each curve represents
data from a single mouse of the
given genotype. Data are repre-
sentative of three experiments.746 A Second Mouse N-formylpeptide Receptor Subtype
appear that differential expansion of an ancestral FPR gene oc-
curred during evolution between humans and mice, resulting
in two mouse receptors that split the functions of human
FPRL1R: FPR2 mediates responses to N-formylpeptides,
whereas LXA4R mediates responses to lipoxin A4. This theory
will need to be tested by additional experiments addressing the
specificity of FPR2 for lipoxin A4 and LXA4R for fMLF. In
addition, these receptors will need to be tested for their speci-
ficity for SAA and HIV-1 T21, which act at human FPRL1R,
and HIV-1 T20, which acts at FPR (16–18). Moreover, alter-
native N-formylpeptides besides fMLF must be considered as
potential physiological ligands for both FPR and FPR2.
In conclusion, since FPR and FPR2 are both expressed
in neutrophils and are differentially sensitive to fMLF, we
propose that they may act sequentially during the inflamma-
tory response: FPR recruits neutrophils in the low concen-
tration portion of an N-formylpeptide gradient, whereas
FPR2 operates closer to the inflammatory focus where
concentrations are expected to be highest and FPR is more
likely to be desensitized. We are currently developing an
FPR2 knockout mouse to test this hypothesis further, as
well as to test the physiological role of FPR2 and its rela-
tionship to human chemoattractant signaling.
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